We have previously shown that the combination of a peptide vaccine (KISIMA) together with VSV-GP induces a high frequency of OVA-specific CD8+ T cells and long-term survival in combination with an immune checkpoint inhibitor in B16-OVA tumor-bearing mice [25]. Here, CD8A is linked to neoplasm.